Drew Sycoff
Known title: DirectorCIK: 0001083139
Drew Sycoff's purchase track record
Drew Sycoff has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/22/2024 | GCTK | $230K | -68.5% | -51.8% | +16.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GCTK | ▲ Buy | Open Market | 182,540 | $230K | 4/22/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
GCTK’s Lōkahi Expands Collaboration & Launches Qare
Glucotrack’s subsidiary Lōkahi Therapeutics has broadened its partnership with the University of Georgia and a German university, marking its first international ai² pipeline project. The company also introduced Qare, a real‑time comparative health platform for GLP‑1 medications, which will be publicly available from October 14. These moves expand Lōkahi’s product reach and could enhance Glucotrack’s overall value proposition.
GCTK’s Lōkahi Expands Collaboration & Launches Qare. Glucotrack’s subsidiary Lōkahi Therapeutics has broadened its partnership with the University of Georgia and a German university, marking its first international ai² pipeline project. The company also introduced Qare, a real‑time comparative health platform for GLP‑1 medications, which will be publicly available from October 14. These moves expand Lōkahi’s product reach and could enhance Glucotrack’s overall value proposition.